<DOC>
	<DOCNO>NCT01243450</DOCNO>
	<brief_summary>The objective ass clinical bioequivalence 0.1 % Retin-A Micro® Gel Spear Pharmaceutical 's generic 0.1 % Tretinoin Microsphere Gel placebo arm .</brief_summary>
	<brief_title>Bioequivalence Study Generic Tretinoin 0.04 % Microsphere Gel , 0.04 % Retin-A Micro® Placebo</brief_title>
	<detailed_description>Acne study</detailed_description>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>A subject eligible participate meet follow inclusion criterion : Normal , healthy male female child adult . Age 12 40 year . Written verbal informed consent must obtain . Subjects age 12 17 ( inclusive ) must sign assent study parent legal guardian must sign informed consent ( per FDA letter 8.21.07 ) . Women childbearing potential must nonpregnant nonnursing , must willing avoid pregnancy course study menstrual cycle follow completion participation study , adequate contraception define regular use two following : oral , injectable contraceptive , condom , spermicide , diaphragm , IUD , implantable contraceptive patch . ( oral contraceptive use least three month injectable contraceptive use least 6 month ) prior enrollment study , abstinence . Have least 20 inflammatory ( papule pustule ) 25 noninflammatory ( open close comedo ) lesion maximum 2 nodulocystic lesion face ( per FDA letter 8.21.07 ) . Global severity score 24 Able refrain use topical acne medication antibiotics treatment period . Considered reliable capable understanding responsibility role study . Exclusion Criteria A subject eligible participate meet none follow exclusion criterion : Subjects active cystic acne evidence 2 facial nodule . More 40 papule and/or pustule ( inflammatory lesion ) More 60 open close comedones/milia ( noninflammatory lesion ) Overall severity grade le 2 great 4 , History allergy hypersensitivity tretinoin . Significant history clinical evidence autoimmune , cardiovascular , gastrointestinal , hematological , hepatic , neurological , pancreatic , renal disease Use systemic retinoid treatment within six month prior study initiation . Oral contraceptive start change within 3 month prior study initiation plan change study . Pregnant breastfeeding . Participation clinical study acne within 4 month precede study initiation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>